Bolt Biotherapeutics

Company snapshot

Bolt Biotherapeutics, Inc., based in the San Francisco Bay Area, is a publicly-traded biotechnology company developing Boltbody™ Immune-stimulating Antibody Conjugates (ISAC), a new class of immuno-oncology therapeutics that have eliminated tumors following systemic administration in preclinical studies and results in the development of immunological memory, which may lead to more durable clinical

• 6 active pipeline program(s) linked via ClinicalTrials.gov.
• 7 US patent(s) indexed to this assignee profile.
• 6 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Bolt Biotherapeutics. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Bolt Biotherapeutics.

1. Jun 8, 2026 Clinical update

   BBI-20201001 — Phase 2

2. May 26, 2026 Clinical update

   BDC-1001, PERTUZUMAB — Phase 2

3. May 23, 2026 Clinical update

   BDC-1001 — Phase 2

4. May 23, 2026 Clinical update

   BDC-1001 — Phase 2

5. May 23, 2026 Clinical update

   BDC-4182 — Phase 2

View all clinical trial activity →

• What is Bolt Biotherapeutics?

  Bolt Biotherapeutics is a pharma organization headquartered in Redwood City, USA. It trades on NYSE under ticker BOLT. Primary therapeutic focus areas include HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2–POSITIVE METASTATIC BREAST CANCER, Advanced HER2-Expressing Solid Tumors., HER2-

• Is Bolt Biotherapeutics publicly traded?

  Yes. Bolt Biotherapeutics is listed with ticker BOLT on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Bolt Biotherapeutics develop or market?

  We link 4 drug profile(s) where Bolt Biotherapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/bolt-biotherapeutics#company-drugs.

• What are the latest developments for Bolt Biotherapeutics?

  In the last 12 months our linked public records show 6 trial program update(s) and 1 US patent grant(s) tied to this profile.

• What therapeutic areas does Bolt Biotherapeutics focus on?

  Bolt Biotherapeutics focuses on HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2–POSITIVE METASTATIC BREAST CANCER, Advanced HER2-Expressing Solid Tumors., HER2-positive Solid Tumors based on our analysis of their pipeline programs and drug development activities.